Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.

Authors :: Hong E
Zampoli M
Beringer PM
Source :: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Jun; Vol. 115 (6), pp. 1204-1207. Date of Electronic Publication: 2024 Feb 22.
Publication Year :: 2024

Subjects :: Humans
Pyridines pharmacokinetics
Pyridines therapeutic use
Pyridines economics
Quinolines therapeutic use
Quinolines pharmacokinetics
Quinolines economics
Drug Costs
Health Services Accessibility economics
Healthcare Disparities economics
Chloride Channel Agonists therapeutic use
Chloride Channel Agonists pharmacokinetics
Chloride Channel Agonists economics
Pyrrolidines therapeutic use
Pyrrolidines pharmacokinetics
Cystic Fibrosis drug therapy
Cystic Fibrosis economics
Benzodioxoles therapeutic use
Benzodioxoles pharmacokinetics
Aminophenols therapeutic use
Aminophenols pharmacokinetics
Aminophenols economics
Drug Combinations
Quinolones therapeutic use
Quinolones pharmacokinetics
Quinolones economics
Indoles economics
Indoles therapeutic use
Indoles pharmacokinetics
Pyrazoles therapeutic use
Pyrazoles pharmacokinetics
Pyrazoles economics

Full Text Access

Tools